精准诊断市场－全球产业规模、份额、趋势、机会、预测：按类型、应用、最终用途、地区和竞争对手划分，2021-2031年

全球精准诊断市场预计将从 2025 年的 165.1 亿美元大幅成长至 2031 年的 304.2 亿美元，复合年增长率为 10.72%。

在该领域，基因测序、生物标记鑑定和分子分析被用于精确定义疾病，从而为个别患者制定个人化治疗策略。推动市场扩张的关键因素包括复杂慢性疾病负担的日益加重以及高通量定序技术成本的持续下降。这些因素共同推动了对精准分子谱分析的需求，而精准分子谱分析对于最大程度地提高临床疗效和减少药物不良反应至关重要。

然而，该行业面临着诸多挑战，特别是构建先进检测平台所需的大量资本投入以及报销途径的不确定性。这两点都可能限制患者获得治疗的机会。个人化医疗联盟强调了这些诊断工具日益融入临床实践的重要性。该联盟在2024年的报告中指出，个人化医疗约占美国食品药物管理局（FDA）前一年核准的所有新治疗分子实体的38%。这项数据凸显了建构完善的诊断基础设施以支持标靶治疗有效实施的迫切需求。

市场驱动因素

癌症和罕见遗传疾病发生率的上升是全球精准诊断市场的主要驱动力。随着这些复杂疾病发生率的增加，医疗系统被迫采用基因测序和分子分析来检测用于标靶治疗的特定生物标记。大量新增病例需要进行精准的基因分析，这凸显了精准诊断的紧迫性。例如，美国癌症协会于2024年1月发布的《2024年癌症事实与数据》报告预测，美国新增癌症病例数将首次超过200万例。面对如此庞大的患者数量，建立健全的诊断框架至关重要，以确保治疗方法能够根据疾病的个别基因特征量身定制，并最大限度地减少无效治疗。

同时，将人工智慧 (AI) 整合到诊断分析中对于解读复杂的基因组数据至关重要。 AI 演算法可以分析定序产生的大量资料集，从而提高侦测速度和准确性。 2024 年 8 月 Fierce Medtech 的报告《FDA 批准的 AI医疗设备清单扩展至 950 件》指出，监管机构已核准了950 件支持 AI 和机器学习的医疗设备，这标誌着该领域监管工作的进展。该领域的经济规模进一步凸显了这些先进解决方案的普及应用。 Exact Sciences 的案例便是一个例证，该公司在 2023 年 12 月的财报中宣布，其 2024 财年的收入将达到 25 亿美元，这反映出精准筛检平台的巨大价值。

市场挑战

开发复杂检测平台所需的大量资本投入以及不确定的报销环境是全球精准诊断市场成长的主要障碍。开发和检验高通量基因组检测方法需要大量的前期投资，但这些投资的回收往往受到支付方政策不一致和报销率下降的威胁。当诊断开发商无法获得稳定的收入来源时，他们就不太愿意筹集必要的研发资金来推出新的分子检测方法。因此，产业的创新周期停滞不前，先进诊断工具的普及也受到限制。

这种财务不稳定直接阻碍了市场扩张，迫使实验室缩减检测项目或推迟新检测方法的商业化，以确保流动性。 2024年，美国临床实验室协会（ACLA）报告称，现行的联邦定价法规将导致约800项常用检测服务在2025年初面临高达15%的报销削减。这种持续的支付水准下行压力造成了不可持续的经济环境，使医疗机构难以维持为广大患者群体提供精准、数据驱动的诊断服务所需的先进基础设施。

市场趋势

液态生物检体技术的进步正从根本上改变市场格局，实现了非侵入性肿瘤分析和即时监测。与传统的切片检查不同，基于血液的检测方法使临床医生能够动态评估微量残存疾病（MRD）和治疗反应。医疗机构正迅速采用这项技术，利用循环肿瘤DNA比影像学检查更早发现復发。 Netara于2025年2月发布的2024年第四季度及全年财报清晰地展现了这一趋势。报告显示，该公司在2024年进行了约528,200例肿瘤检测，较去年同期成长54.9%。这显示液体分子检测在肿瘤治疗领域的应用取得了显着进展。

同时，精准诊断技术向神经系统领域的多元化发展正在推动市场成长，尤其是在阿兹海默症管理方面。随着新治疗方法的出现，人们越来越需要更方便的筛检工具来取代侵入性的脑脊髓液分析和高成本的PET扫描。基于血液的生物标誌物，例如pTau-217，在这一转变过程中发挥关键作用，为识别淀粉样蛋白病理提供了可扩展的方法。 2025年4月，《MedTech Dive》杂誌发表了一篇题为「Labcorp推出血液检测以加速阿兹海默症诊断」的报导，证实了这一进展。报导中，Labcorp宣布其pTau-217确诊检测的敏感度和特异度均达到了95%。向神经系统适应症的拓展显着拓宽了市场范围，使其不再局限于传统的以肿瘤学为中心的框架。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球精准诊断市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（基因检测、直接消费者检测、专业检测、其他）
  • 依应用领域（肿瘤学、呼吸系统疾病、皮肤病、中枢神经系统疾病、免疫学、遗传性疾病等）
  • エンドユーザー别（病院、临床检查室、その他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美精准诊断市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲先进诊断市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区精准诊断市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲精准诊断市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲精准诊断市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球精准诊断市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Abbott Laboratories Inc.
• F. Hoffmann-La Roche Ltd.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• bioMerieux SA
• Becton, Dickinson and Company
• Danaher Corporation
• QIAGEN NV
• Hologic Inc.
• Agilent Technologies Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Precision Diagnostics Market is projected to experience substantial growth, rising from USD 16.51 Billion in 2025 to USD 30.42 Billion by 2031, representing a CAGR of 10.72%. This sector employs genomic sequencing, biomarker identification, and molecular analysis to define diseases with granular specificity, thereby allowing for customized therapeutic strategies for individual patients. Key drivers propelling this market expansion include the escalating burden of complex chronic diseases and the steady decrease in costs related to high-throughput sequencing technologies. Together, these factors drive the demand for accurate molecular profiling, which is essential for maximizing clinical results and reducing adverse drug reactions.

However, the industry faces significant obstacles, notably the high capital investment needed to build sophisticated testing platforms and the uncertainty surrounding reimbursement pathways, both of which can restrict patient access. The increasing integration of these diagnostic tools into clinical practice is highlighted by the Personalized Medicine Coalition, which reported in 2024 that personalized medicines comprised approximately 38 percent of all new therapeutic molecular entities approved by the Food and Drug Administration the previous year. This statistic emphasizes the critical need for precise diagnostic infrastructure to support the effective deployment of targeted therapies.

Market Driver

The rising prevalence of oncology and rare genetic disorders acts as a major catalyst for the Global Precision Diagnostics Market. As the incidence of these complex conditions increases, healthcare systems are compelled to adopt genomic sequencing and molecular analysis to detect specific biomarkers for targeted treatment. This urgency is underscored by the sheer volume of new diagnoses requiring precise profiling; for instance, the American Cancer Society's "Cancer Facts & Figures 2024" report from January 2024 projected that new cancer cases in the United States would exceed 2 million for the first time. Such growing patient numbers necessitate robust diagnostic frameworks to ensure therapies are aligned with the individual genetic characteristics of a disease, thereby minimizing ineffective treatments.

Simultaneously, the incorporation of artificial intelligence into diagnostic analytics is becoming essential for interpreting intricate genomic data. AI algorithms are capable of analyzing the massive datasets produced by sequencing, enhancing both detection speed and accuracy. Regulatory progress in this area was noted in an August 2024 Fierce Medtech report titled "FDA's list of authorized AI medical devices grows to 950," which indicated that regulators had cleared 950 AI and machine learning-enabled medical devices. The financial magnitude of this sector further confirms the adoption of these advanced solutions, as evidenced by Exact Sciences, which reported 2024 revenues of $2.50 billion for the fiscal year ending December 2023, reflecting the substantial value attributed to precision screening platforms.

Market Challenge

The significant capital expenditure required to develop complex testing platforms, along with uncertain reimbursement landscapes, presents a major barrier to the growth of the Global Precision Diagnostics Market. Creating and validating high-throughput genomic assays entails substantial upfront costs, yet the return on this investment is often threatened by inconsistent payer policies and declining fee schedules. When diagnostic developers cannot rely on stable revenue streams, they are less likely to fund the research needed to introduce novel molecular tests, which in turn stalls the industry's innovation cycle and limits the availability of advanced diagnostic tools.

This financial instability directly impedes market expansion by forcing laboratories to scale back their test menus or postpone the commercialization of new assays to conserve liquidity. In 2024, the American Clinical Laboratory Association reported that approximately 800 frequently ordered laboratory services were facing scheduled reimbursement cuts of up to 15 percent by early 2025 due to current federal rate-setting regulations. Such persistent downward pressure on payment rates creates an unsustainable economic environment, making it difficult for providers to maintain the sophisticated infrastructure required to deliver precise, data-driven diagnostic care to the broader patient population.

Market Trends

The advancement of liquid biopsy capabilities is fundamentally transforming the market by facilitating non-invasive tumor profiling and real-time monitoring. Unlike traditional tissue biopsies, blood-based assays enable clinicians to dynamically assess Minimal Residual Disease (MRD) and treatment response. This technology is being rapidly adopted as providers leverage circulating tumor DNA to detect recurrence earlier than imaging allows. This trend is exemplified by Natera's February 2025 report on its "Fourth Quarter and Full Year 2024 Financial Results," which noted the company performed roughly 528,200 oncology tests in 2024, a 54.9 percent increase from the prior year, illustrating the significant shift toward incorporating fluid-based molecular testing into oncological care.

Concurrently, the diversification of precision diagnostics into neurology is driving market growth, particularly regarding Alzheimer's disease management. With the emergence of new therapies, there is a need for accessible screening tools to replace invasive cerebrospinal fluid analysis and costly PET scans. Blood-based biomarkers such as pTau-217 are central to this transition, offering a scalable method for identifying amyloid pathology. This progress was confirmed in an April 2025 MedTech Dive article titled "Labcorp launches blood test to accelerate Alzheimer's diagnosis," where Labcorp announced that its confirmatory pTau-217 test achieved 95 percent sensitivity and specificity. Expanding into neurological indications significantly broadens the market scope beyond its traditional focus on oncology.

Key Market Players

• Abbott Laboratories Inc.
• F. Hoffmann-La Roche Ltd.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• bioMerieux SA
• Becton, Dickinson and Company
• Danaher Corporation
• QIAGEN N.V.
• Hologic Inc.
• Agilent Technologies Inc

Report Scope

In this report, the Global Precision Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Precision Diagnostics Market, By Type

• Genetic Tests
• Direct to Consumer Tests
• Esoteric Tests
• Others

Precision Diagnostics Market, By Application

• Oncology
• Respiratory Diseases
• Skin Diseases
• CNS Disorders
• Immunology
• Genetic Diseases
• Others

Precision Diagnostics Market, By End-Use

• Hospitals
• Clinical Laboratories
• Others

Precision Diagnostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Precision Diagnostics Market.

Available Customizations:

Global Precision Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Precision Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Genetic Tests, Direct to Consumer Tests, Esoteric Tests, Others)
  • 5.2.2. By Application (Oncology, Respiratory Diseases, Skin Diseases, CNS Disorders, Immunology, Genetic Diseases, Others)
  • 5.2.3. By End-Use (Hospitals, Clinical Laboratories, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Precision Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End-Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Precision Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End-Use
  • 6.3.2. Canada Precision Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End-Use
  • 6.3.3. Mexico Precision Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End-Use

7. Europe Precision Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End-Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Precision Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End-Use
  • 7.3.2. France Precision Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End-Use
  • 7.3.3. United Kingdom Precision Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End-Use
  • 7.3.4. Italy Precision Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End-Use
  • 7.3.5. Spain Precision Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End-Use

8. Asia Pacific Precision Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End-Use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Precision Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End-Use
  • 8.3.2. India Precision Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End-Use
  • 8.3.3. Japan Precision Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End-Use
  • 8.3.4. South Korea Precision Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End-Use
  • 8.3.5. Australia Precision Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End-Use

9. Middle East & Africa Precision Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End-Use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Precision Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End-Use
  • 9.3.2. UAE Precision Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End-Use
  • 9.3.3. South Africa Precision Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End-Use

10. South America Precision Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End-Use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Precision Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End-Use
  • 10.3.2. Colombia Precision Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End-Use
  • 10.3.3. Argentina Precision Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End-Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Precision Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Abbott Laboratories Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. F. Hoffmann-La Roche Ltd.
• 15.3. Siemens Healthineers AG
• 15.4. Thermo Fisher Scientific Inc.
• 15.5. bioMerieux SA
• 15.6. Becton, Dickinson and Company
• 15.7. Danaher Corporation
• 15.8. QIAGEN N.V.
• 15.9. Hologic Inc.
• 15.10. Agilent Technologies Inc

16. Strategic Recommendations

17. About Us & Disclaimer